Echo Therapeutics (ECTE) 2.62 $ECTE
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations
M2 - Mon Feb 02, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dl4jfq/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations" report to their offering. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. U.S. Glucose Testing Markets 2014 analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles - Click the link below to view the full list of companies featured in this extensive report - Abaxis, Inc. - Abbott Laboratories - AgaMatrix - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - GlySens - GlySure Limited - Grove Instruments - Hainice Medical - HemoCue (a Quest Diagnostics company) - Johnson & Johnson - Luminous Medical - Medtronic - Nipro Corporation - Nova Biomedical - OrSense - Polymer Technology Systems - Radiometer Medical - Roche - 77 Elektronika Kft. - Siemens AG For more information visit http://www.researchandmarkets.com/research/dl..._s_glucose
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Echo Therapeutics Restores Pact with MTIA, Issues Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:05PM CST
Echo Therapeutics Inc. (ECTE), a firm engaged in the development of transdermal skin permeation and diagnostic medical devices, recently announced re-establishment of its contract with Medical Technologies Innovation Asia (MTIA), Ltd.
ECTE: 2.62 (+0.06), BABY: 36.96 (-0.03), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Echo Therapeutics and Medical Technologies Innovation Asia (MTIA) Re-affirm Operational Partnership
PR Newswire - Wed Jan 21, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring, and associated technologies, announced today that it has re-established its operational and strategic partnership with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, and has initiated the technology transfer process. The partnership is designed to enable close cooperation between the two companies in order to address China's growing demand for both glucose monitoring and transdermal drug delivery solutions.
ECTE: 2.62 (+0.06)
Global Continuous Glucose Monitoring System Market Overview and Forecasts 2014 - 2020
M2 - Thu Jan 08, 8:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xn4hcp/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System - Glucose Sensors, Geographical Analysis, Artificial Pancreas, Size, Market Overview, Price, Industry Analysis, Market Growth, Market Share, Forecasts 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgm Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/xn...continuous
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), PODD: 32.00 (-0.07), MDT: 75.26 (+0.33)
Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy
PR Newswire - Tue Jan 06, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive glucose monitoring and associated technologies, announced today that the Company rehired key members of its Research & Development team to support the implementation of a new corporate strategy. The Research & Development team, led by Tom Bishop, Vice President of Operations and Product Development, will refine and adapt Echo's current core transdermal technology for consumer and medical applications in analyte measurement.
ECTE: 2.62 (+0.06)
New finance chief at Echo
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:55AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer
PR Newswire - Tue Dec 30, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Alan W. Schoenbart, CPA, a senior executive with more than thirty years of financial management experience, joined the Company as Chief Financial Officer effective December 29, 2014.
ECTE: 2.62 (+0.06)
OTC Daily Alert Stock Watch - Echo Therapeutics (Nasdaq: ECTE)
WorldStockWire - Mon Dec 29, 2:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ECTE: 2.62 (+0.06)
Echo Therapeutics elects Scott W. Hollander as CEO
M2 - Wed Dec 24, 3:45AM CST
Medical company Echo Therapeutics (NasdaqCM:ECTE) reported on Tuesday the addition of Scott W. Hollander as its chief executive officer effective 22 December 2014.
ECTE: 2.62 (+0.06)
New chief at Echo Therapeutics
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:05AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer
PR Newswire - Tue Dec 23, 7:36AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Scott W. Hollander has been appointed Chief Executive Officer effective December 22, 2014. Mr. Hollander has more than 20 years of experience in the medical device, pharmaceutical and capital equipment industries, and most recently served as Vice President, Business Development, Otsuka Pharmaceuticals as well as President and Chief Executive Officer of Interpharma-Praha, an Otsuka subsidiary company.
ECTE: 2.62 (+0.06)
Echo Therapeutics accounting firm quits
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 3:15PM CST
ECTE: 2.62 (+0.06)
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), PODD: 32.00 (-0.07), MDT: 75.26 (+0.33)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:45AM CST
ALOG: 86.55 (+1.60), VBIV: 3.01 (+0.01), PRTK: 26.95 (+0.65), TPLM: 5.68 (+0.06), MIND: 6.94 (+0.01), SSE: 5.23 (+0.22), ALLT: 9.15 (+0.02), EGY: 5.86 (-0.06), GBR: 1.48 (-0.10), ECTE: 2.62 (+0.06), PWE: 2.45 (+0.02), GDP: 3.58 (+0.29), LAYN: 7.93 (+0.22), WRES: 1.27 (+0.01), CALA: 16.11 (+0.62), AKER: 3.50 (+0.20), CVEO: 3.87 (+0.15), CNIT: 3.42 (+0.08), CYRN: 2.83 (+0.23), CRK: 6.09 (+0.46)
Echo Therapeutics' CFO resigns after four months on job
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:45PM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 5:49AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 5:09PM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 19, 5:00PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced its financial results for the quarter ended September 30, 2014. Echo's Quarterly Report on Form 10-Q, when filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 2.62 (+0.06)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014
M2 - Thu Feb 05, 3:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/ltppcg/diabetes) has announced the addition of the "Global Diabetes, Metabolic Syndrome and Cardiovascular Disease Markets Overview 2014" report to their offering. Proactive strategies for prevention of the disease are being put in place by international health organizations such as the World Health Organization (WHO), as well as by the health departments of industrialized and developing countries, and even at the local level where food ingredients regulations are being passed. There has been a dramatic increase in the incidence of diabetes worldwide, which has been exacerbated by the growing obesity problem across the globe. Once thought of as primarily a childhood disease--sometimes referred to as juvenile diabetes, now mostly Type 1 diabetes--the obesity crisis linked to the adoption of a high-fat, high-carbohydrate, high-calorie American diet has resulted in skyrocketing rates of diabetes among adults across the world. To compound the global diabetes epidemic, health professionals are witnessing an alarming increase in inflammatory diseases resulting from adult onset (i.e., Type 2) diabetes. This phenomenon is referred to as "metabolic syndrome" where a confluence of inflammatory conditions occur along with the diabetes. As a result, growing evidence appears to show that metabolic syndrome makes the diabetic patient susceptible to degenerative health conditions such as cardiovascular disease, stroke and, now believed, Alzheimer's disease. As the diabetes epidemic escalates, a new sense of urgency has taken hold. This publication report charts the changing landscape of the global diabetic population and explores the added health concerns resulting from the metabolic syndrome phenomenon and one of its major risk factors: cardiovascular disease (CVD). Furthermore, this study evaluates widely-accepted therapeutic approaches to diabetes that are currently in use, while providing an in-depth analysis of emerging technologies that will be used to treat diabetes and other inflammatory diseases in the future. Key Topics Covered: 1. Overview 2. Introduction 3. Understanding the Metabolic Conditions Underlying and Associated with Diabetes 4. Pharmaceutical Industry and the Anti-Diabetes Market 5. Non-Insulin Anti-Diabetes Products 6. Insulin 7. Emerging Anti-Diabetes Technologies and Products 8. Diagnosing Diabetes Using In Vitro Laboratory Tests 9. Market Trends, Challenges and Strategic Options 10. Company Profiles Companies Mentioned: 30 of the 66 companies featured in this extensive report - Abbott Laboratories - Abbvie - Amgen - Animas (part of Johnson & Johnson) - Asante - Astellas Pharma, Inc. - AstraZeneca Plc - Bayer - Becton, Dickinson and Company - Boehringer Ingelheim - Bristol Myers Squibb - Daiichi Sankyo - DexCom - Echo Therapeutics, Inc. - Eli Lilly - Generex Biotechnology Corporation - GlaxoSmithKline Plc - Johnson & Johnson - Kowa Pharmaceuticals - Lexicon Pharmaceuticals - Medtronic - Merck & Company, Inc. - Mitsubishi Tanabe Pharma Corporation - Novartis - Novo Nordisk - Pfizer - Roche Diagnostics - Sanofi-Aventis - Taisho Pharmaceuticals - Takeda For more information visit http://www.researchandmarkets.com/research/ltppcg/diabetes
ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), LXRX: 0.89 (unch), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), NVO: 43.76 (+0.61), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), NVS: 102.20 (-0.17)
U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations
M2 - Mon Feb 02, 2:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/dl4jfq/u_s_glucose) has announced the addition of the "U.S. Glucose Testing Markets 2014: Clinical Measurement Devices, Reagents and Supplies as Utilized in Hospitals, Clinics, Doctor's Offices and At-Home Care Locations" report to their offering. This report describes the specific market segments for blood glucose testing and diabetes management in the U.S. market. It reviews all of the generally-accepted clinical analytical methods that are currently in use today for measuring serum, plasma or whole-blood glucose concentrations. Additionally, this study examines clinical measurement devices, reagents and supplies as utilized in hospitals, clinics, doctor's offices and at-home care locations. Although the blood glucose testing segment of the in vitro diagnostics (IVD) industry is mature, several segments of the market, such as home testing devices for diabetes management and point of care (POC) instruments for use in professional settings, will exhibit strong growth. Direct access testing has emerged as a strong force in the blood glucose testing segment, and non-invasive and minimally-invasive testing now represent major new areas for the application of IVD testing. U.S. Glucose Testing Markets 2014 analyzes almost all of the companies known to be marketing, manufacturing or developing glucose testing products for the U.S. market. Each company is discussed in extensive depth with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Detailed tables and charts with sales forecasts and market data are also included. Key Topics Covered: 1. Overview 2. Diabetes 3. Market Analysis: Size, Growth, Share and Competitors 4. Glucose Diagnostic and Monitoring Recommendations 5. Glucose Testing Technology Platforms and Consumable Products 6. Glucose Testing Devices on the Market 7. Business Trends in Glucose Testing 8. Technology Trends 9. Company Profiles - Click the link below to view the full list of companies featured in this extensive report - Abaxis, Inc. - Abbott Laboratories - AgaMatrix - B. Braun Melsungen - Beckman Coulter - Bionime - Bio-Rad Laboratories, Inc. - BioTex - Calisto Medical - Cambridge Sensors - DexCom - Diagnostic Devices/Prodigy Diabetes Care - DiaSys - Echo Therapeutics - GlySens - GlySure Limited - Grove Instruments - Hainice Medical - HemoCue (a Quest Diagnostics company) - Johnson & Johnson - Luminous Medical - Medtronic - Nipro Corporation - Nova Biomedical - OrSense - Polymer Technology Systems - Radiometer Medical - Roche - 77 Elektronika Kft. - Siemens AG For more information visit http://www.researchandmarkets.com/research/dl..._s_glucose
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), ABT: 46.09 (+0.87), MDT: 75.26 (+0.33), ABAX: 60.93 (+0.65)
Echo Therapeutics Restores Pact with MTIA, Issues Patent - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jan 22, 4:05PM CST
Echo Therapeutics Inc. (ECTE), a firm engaged in the development of transdermal skin permeation and diagnostic medical devices, recently announced re-establishment of its contract with Medical Technologies Innovation Asia (MTIA), Ltd.
ECTE: 2.62 (+0.06), BABY: 36.96 (-0.03), INGN: 33.53 (+2.32), SURG: 4.44 (-0.02)
Echo Therapeutics and Medical Technologies Innovation Asia (MTIA) Re-affirm Operational Partnership
PR Newswire - Wed Jan 21, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring, and associated technologies, announced today that it has re-established its operational and strategic partnership with Medical Technologies Innovation Asia (MTIA), Ltd., Hong Kong, and has initiated the technology transfer process. The partnership is designed to enable close cooperation between the two companies in order to address China's growing demand for both glucose monitoring and transdermal drug delivery solutions.
ECTE: 2.62 (+0.06)
Global Continuous Glucose Monitoring System Market Overview and Forecasts 2014 - 2020
M2 - Thu Jan 08, 8:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/xn4hcp/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System - Glucose Sensors, Geographical Analysis, Artificial Pancreas, Size, Market Overview, Price, Industry Analysis, Market Growth, Market Share, Forecasts 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from self-monitoring blood glucose devices (SMBG). SMBG devices are cheaper and easy to use and have an less stringent approval process from authorities like FDA. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. CGM system market has seen good growth rates in past three years. Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgm Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/xn...continuous
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), PODD: 32.00 (-0.07), MDT: 75.26 (+0.33)
Echo Therapeutics Re-hires Key Product Development Team In Support of New Corporate Strategy
PR Newswire - Tue Jan 06, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on non-invasive glucose monitoring and associated technologies, announced today that the Company rehired key members of its Research & Development team to support the implementation of a new corporate strategy. The Research & Development team, led by Tom Bishop, Vice President of Operations and Product Development, will refine and adapt Echo's current core transdermal technology for consumer and medical applications in analyte measurement.
ECTE: 2.62 (+0.06)
New finance chief at Echo
Seeking Alpha - at Seeking Alpha - Tue Dec 30, 8:55AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Appoints Alan W. Schoenbart as Chief Financial Officer
PR Newswire - Tue Dec 30, 6:50AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Alan W. Schoenbart, CPA, a senior executive with more than thirty years of financial management experience, joined the Company as Chief Financial Officer effective December 29, 2014.
ECTE: 2.62 (+0.06)
OTC Daily Alert Stock Watch - Echo Therapeutics (Nasdaq: ECTE)
WorldStockWire - Mon Dec 29, 2:30PM CST
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
ECTE: 2.62 (+0.06)
Echo Therapeutics elects Scott W. Hollander as CEO
M2 - Wed Dec 24, 3:45AM CST
Medical company Echo Therapeutics (NasdaqCM:ECTE) reported on Tuesday the addition of Scott W. Hollander as its chief executive officer effective 22 December 2014.
ECTE: 2.62 (+0.06)
New chief at Echo Therapeutics
Seeking Alpha - at Seeking Alpha - Tue Dec 23, 9:05AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer
PR Newswire - Tue Dec 23, 7:36AM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company focused on skin permeation, continuous glucose monitoring and associated technologies, today announced that Scott W. Hollander has been appointed Chief Executive Officer effective December 22, 2014. Mr. Hollander has more than 20 years of experience in the medical device, pharmaceutical and capital equipment industries, and most recently served as Vice President, Business Development, Otsuka Pharmaceuticals as well as President and Chief Executive Officer of Interpharma-Praha, an Otsuka subsidiary company.
ECTE: 2.62 (+0.06)
Echo Therapeutics accounting firm quits
Seeking Alpha - at Seeking Alpha - Fri Dec 12, 3:15PM CST
ECTE: 2.62 (+0.06)
Global Continuous Glucose Monitoring System 2014 - 2020
M2 - Fri Dec 12, 2:56AM CST
Research and Markets (http://www.researchandmarkets.com/research/ccxjt3/global_continuous) has announced the addition of the "Global Continuous Glucose Monitoring System 2014 - 2020" report to their offering. Emergence of continuous glucose monitoring systems is a major breakthrough in the glucose monitoring for diabetic patients. Medtronic and Dexcom are the only major players in this industry followed by Abbott in few regions. Companies are focusing more on research and development before introducing their products in the market. CGMS are highly regulated and go through strict tests before being approved. CGM manufacturers have faced competition from Finger based self-monitoring blood glucose devices. SMBG devices are cheaper and easy to use and are easily approved by the authorities. SMBG has more number of players and larger market share. However, CGM systems have been able to make a good market entry in the U.S. and are following the trend in other territories. . CGM system market has seen good growth rates in past three years. Medtronic and Dexcom have introduced new systems which have witnessed lower frequency of errors. The MARD value for new sensors has decreased, new devices need lesser calibrations per day and most of the devices are approved for pediatric use. This has led to 50-60 percent jump in the revenues of some manufacturers. Global Continuous Glucose Monitoring System Market - CGM Market - Real Time Monitoring - Integrated Insulin Pumps - Blood Glucose - Manufacturers - Global Health - IPRO Glucose - MARD - SMBG - Growing Diabetic Population - Type 1 & 2 Diabetes - Nocturnal Hypoglycemia Key Topics Covered: Chapter 1. Executive Summary Chapter 2. Market Overview Chapter 3. Market Determinants Chapter 4. Sector Analysis: Diabetes Care Chapter 5. Cgms Market By Devices Chapter 6. By Application Chapter 7. Competitive Intelligence Chapter 8. Market Share Analysis Chapter 9. Geographical Analysis Chapter 10. Corporate Profile: Benchmark Study - Medtronic Inc. - Dexcom - Abbott - Johnson And Johnson (J&J) (Animas Corp) - Insulet Corp - Tandem Diabetes - Echo Therapeutics For more information visit http://www.researchandmarkets.com/research/cc...continuous
ECTE: 2.62 (+0.06), JNJ: 99.62 (+1.18), PODD: 32.00 (-0.07), MDT: 75.26 (+0.33)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Dec 10, 11:45AM CST
ALOG: 86.55 (+1.60), VBIV: 3.01 (+0.01), PRTK: 26.95 (+0.65), TPLM: 5.68 (+0.06), MIND: 6.94 (+0.01), SSE: 5.23 (+0.22), ALLT: 9.15 (+0.02), EGY: 5.86 (-0.06), GBR: 1.48 (-0.10), ECTE: 2.62 (+0.06), PWE: 2.45 (+0.02), GDP: 3.58 (+0.29), LAYN: 7.93 (+0.22), WRES: 1.27 (+0.01), CALA: 16.11 (+0.62), AKER: 3.50 (+0.20), CVEO: 3.87 (+0.15), CNIT: 3.42 (+0.08), CYRN: 2.83 (+0.23), CRK: 6.09 (+0.46)
Echo Therapeutics' CFO resigns after four months on job
Seeking Alpha - at Seeking Alpha - Wed Nov 26, 3:45PM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Q3 results
Seeking Alpha - at Seeking Alpha - Thu Nov 20, 5:49AM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics reports Q3 loss
Seeking Alpha - at Seeking Alpha - Wed Nov 19, 5:09PM CST
ECTE: 2.62 (+0.06)
Echo Therapeutics Announces Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 19, 5:00PM CST
Echo Therapeutics, Inc. (NASDAQ: ECTE), a medical device company, today announced its financial results for the quarter ended September 30, 2014. Echo's Quarterly Report on Form 10-Q, when filed with the SEC, will be available by visiting the Investors section of Echo's website at www.echotx.com.
ECTE: 2.62 (+0.06)
Research and Markets: Mycosis Fungoides Therapeutics Pipeline Review, H2 2014 Report Featuring Sanofi, Seattle Genetics, Inc, Echo Therapeutics, Inc. & Actelion Ltd
Business Wire - Thu Nov 06, 4:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/mlg9h9/mycosis_fungoides) has announced the addition of the "Mycosis Fungoides - Pipeline Review, H2 2014" report to their offering.
ECTE: 2.62 (+0.06), SGEN: 31.57 (+0.36)
